➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Moodys
McKinsey
AstraZeneca
Baxter

Last Updated: May 8, 2021

DrugPatentWatch Database Preview

RECARBRIO Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Recarbrio, and what generic alternatives are available?

Recarbrio is a drug marketed by Msd Merck Co and is included in one NDA. There is one patent protecting this drug.

This drug has fifty-seven patent family members in thirty-four countries.

The generic ingredient in RECARBRIO is cilastatin sodium; imipenem; relebactam. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cilastatin sodium; imipenem; relebactam profile page.

DrugPatentWatch® Generic Entry Outlook for Recarbrio

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 19, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Get Started for $10

Summary for RECARBRIO
International Patents:57
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 2
Formulation / Manufacturing:see details
Drug Prices: Drug price information for RECARBRIO
What excipients (inactive ingredients) are in RECARBRIO?RECARBRIO excipients list
DailyMed Link:RECARBRIO at DailyMed
Drug patent expirations by year for RECARBRIO
Drug Prices for RECARBRIO

See drug prices for RECARBRIO

DrugPatentWatch® Estimated Generic Entry Opportunity Date for RECARBRIO
Generic Entry Date for RECARBRIO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RECARBRIO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Atrium HealthPhase 4
Merck Sharp & Dohme Corp.Phase 4
Joseph L. Kuti, PharmDPhase 1

See all RECARBRIO clinical trials

Pharmacology for RECARBRIO

US Patents and Regulatory Information for RECARBRIO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Msd Merck Co RECARBRIO cilastatin sodium; imipenem; relebactam POWDER;INTRAVENOUS 212819-001 Jul 16, 2019 RX Yes Yes   Get Started for $10   Get Started for $10 Y Y   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for RECARBRIO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2666774 CA 2020 00037 Denmark   Get Started for $10 PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217
2231667 122020000034 Germany   Get Started for $10 PRODUCT NAME: RELEBACTAM ODER EIN MONOHYDRAT DAVON; NAT. REGISTRATION NO/DATE: EU/1/19/1420 20200213; FIRST REGISTRATION: EU EU/1/191420 20200213
2231667 132020000000067 Italy   Get Started for $10 PRODUCT NAME: RELEBACTAM O UN SUO MONOIDRATO(RECARBRIO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1420, 20200217
2666774 PA2020517 Lithuania   Get Started for $10 PRODUCT NAME: RELEBAKTAMAS, PASIRINKTINAI MONOHIDRATO PAVIDALU, IR IMIPENEMAS; REGISTRATION NO/DATE: EU/1/19/1420 20200213
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
McKesson
Baxter
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.